文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

制定精确打击恶性黑素瘤的个体化策略。

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.

机构信息

Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Int J Mol Sci. 2024 May 4;25(9):5023. doi: 10.3390/ijms25095023.


DOI:10.3390/ijms25095023
PMID:38732242
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11084485/
Abstract

Melanoma is the most severe and fatal form of skin cancer, resulting from multiple gene mutations with high intra-tumor and inter-tumor molecular heterogeneity. Treatment options for patients whose disease has progressed beyond the ability for surgical resection rely on currently accepted standard therapies, notably immune checkpoint inhibitors and targeted therapies. Acquired resistance to these therapies and treatment-associated toxicity necessitate exploring novel strategies, especially those that can be personalized for specific patients and/or populations. Here, we review the current landscape and progress of standard therapies and explore what personalized oncology techniques may entail in the scope of melanoma. Our purpose is to provide an up-to-date summary of the tools at our disposal that work to circumvent the common barriers faced when battling melanoma.

摘要

黑色素瘤是最严重和致命的皮肤癌形式,是由多种基因突变引起的,具有高肿瘤内和肿瘤间的分子异质性。对于那些疾病已经发展到无法通过手术切除的患者,治疗选择依赖于目前公认的标准治疗方法,特别是免疫检查点抑制剂和靶向治疗。对这些治疗方法的获得性耐药性和治疗相关毒性需要探索新的策略,特别是那些可以针对特定患者和/或人群进行个性化的策略。在这里,我们回顾了标准治疗的现状和进展,并探讨了个性化肿瘤学技术在黑色素瘤领域可能涉及的内容。我们的目的是提供一个最新的综述,介绍我们目前用来克服治疗黑色素瘤时常见障碍的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/769373638eca/ijms-25-05023-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/88648e34b90d/ijms-25-05023-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/acc8e82a72f7/ijms-25-05023-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/769373638eca/ijms-25-05023-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/88648e34b90d/ijms-25-05023-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/acc8e82a72f7/ijms-25-05023-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ac/11084485/769373638eca/ijms-25-05023-g003.jpg

相似文献

[1]
Development of Personalized Strategies for Precisely Battling Malignant Melanoma.

Int J Mol Sci. 2024-5-4

[2]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[3]
Interventions for melanoma in situ, including lentigo maligna.

Cochrane Database Syst Rev. 2014-12-19

[4]
The melanoma MEGA-study: Integrating proteogenomics, digital pathology, and AI-analytics for precision oncology.

J Proteomics. 2025-6-16

[5]
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.

Br J Dermatol. 2025-1-24

[6]
Neoadjuvant treatment for stage III and IV cutaneous melanoma.

Cochrane Database Syst Rev. 2023-1-17

[7]
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Cochrane Database Syst Rev. 2015-12-1

[8]
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Cochrane Database Syst Rev. 2015-5-16

[9]
Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation.

J Cancer Res Clin Oncol. 2021-5

[10]
Cemiplimab in the treatment of metastatic basal cell carcinoma.

Future Oncol. 2025-7

引用本文的文献

[1]
Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?

Skin Health Dis. 2025-4-22

[2]
Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Front Immunol. 2024-12-6

[3]
Advances in Melanoma: From Genetic Insights to Therapeutic Innovations.

Biomedicines. 2024-8-14

[4]
Metastatic Nodular Melanoma with Angiosarcomatous Transdifferentiation-A Case Report and Review of the Literature.

Diagnostics (Basel). 2024-6-21

本文引用的文献

[1]
CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.

Cells. 2024-1-26

[2]
A Potential "Anti-Warburg Effect" in Circulating Tumor Cell-mediated Metastatic Progression?

Aging Dis. 2024-1-11

[3]
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

Lancet. 2024-2-17

[4]
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.

Cells. 2023-11-30

[5]
Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.

Front Immunol. 2023

[6]
Identification and targeting of cancer-associated fibroblast signature genes for prognosis and therapy in Cutaneous melanoma.

Comput Biol Med. 2023-12

[7]
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses.

Nat Biotechnol. 2024-8

[8]
Pten knockout affects drug resistance differently in melanoma and kidney cancer.

Pharmacol Rep. 2023-10

[9]
TIGIT, a novel immune checkpoint therapy for melanoma.

Cell Death Dis. 2023-7-26

[10]
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.

Ther Adv Med Oncol. 2023-7-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索